Ray Taylor
BioCryst Pharmaceuticals (United States)(US)
Publications by Year
Research Areas
Viral Infections and Vectors, Mosquito-borne diseases and control, Viral Infections and Outbreaks Research, Virology and Viral Diseases, SARS-CoV-2 and COVID-19 Research
Most-Cited Works
- → Efficacy of the broad-spectrum antiviral compound BCX4430 against Zika virus in cell culture and in a mouse model(2016)160 cited
- → An update on the progress of galidesivir (BCX4430), a broad-spectrum antiviral(2021)77 cited
- → Galidesivir limits Rift Valley fever virus infection and disease in Syrian golden hamsters(2018)72 cited
- → A direct-acting antiviral drug abrogates viremia in Zika virus–infected rhesus macaques(2020)25 cited
- → Galidesivir, a Direct-Acting Antiviral Drug, Abrogates Viremia in Rhesus Macaques Challenged with Zika Virus(2017)19 cited
- → Activity of Galidesivir in a Hamster Model of SARS-CoV-2(2021)17 cited
- → Pharmacokinetics and Safety of the Nucleoside Analog Antiviral Drug Galidesivir Administered to Healthy Adult Subjects(2022)15 cited
- → Efficacy of Galidesivir against Ebola Virus Disease in Rhesus Monkeys(2017)11 cited
- → BCX4430, a Broad-Spectrum Adenosine Analog Direct-Acting Antiviral Drug, Abrogates Viremia in Rhesus Macaques Challenged With Zika Virus(2016)5 cited
- → Virus-like Structures in Lupus Erythematosus(1970)